Author: Brenda Marie Rivers|| Date Published: July 27, 2020
Moderna has been awarded a potential $472M contract modification by the Biomedical Advanced Research and Development Authority to expand late-stage clinical trials of a messenger RNA-based vaccine candidate for the novel coronavirus.
BARDA’s additional funding commitment increases the potential value of the initial contract to $955M, the company said Sunday.
Under the modification, BARDA pledged funds to support Phase 3 tests of Moderna’s mRNA-1273 vaccine including a study to be conducted with 30K participants.
The biotechnology firm will perform the participant-based trials with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases’ COVID-19 Prevention Trials Network.
“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” said Moderna CEO Stephane Bancel.
The company aims to deliver 500M to 1B doses of the potential COVID-19 vaccine starting next year as part of the Trump administration’s Operation Warp Speed.
Sally Wallace has been promoted to executive vice president and chief operating officer at Leonardo DRS. The Arlington, Virginia-based company said Tuesday…
IT systems integrator 22nd Century Technologies, Inc. has completed its acquisition of BT Federal, the U.S. government contracting arm of BT Group. Government…
The National Geospatial-Intelligence Agency has awarded Raytheon a five-year, $110.4 million contract to support the Geospatial-Intelligence Data Transformation Service IV…
The U.S. Air Force has awarded InDyne a potential $1.1 billion indefinite-delivery/indefinite-quantity contract to support the service’s missile warning and…
